A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006.
about
Progress of molecular targeted therapies for prostate cancersAnti-angiogenesis in prostate cancer: knocked down but not outCombined inhibition of epidermal growth factor receptor and cyclooxygenase-2 leads to greater anti-tumor activity of docetaxel in advanced prostate cancerThe lysine specific demethylase-1 (LSD1/KDM1A) regulates VEGF-A expression in prostate cancerEffect of angiogenesis inhibitor bevacizumab on survival in patients with cancer: a meta-analysis of the published literature.Docetaxel plus oral metronomic cyclophosphamide: a phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients.Risks and benefits with bevacizumab: evidence and clinical implications.Targeted therapy in prostate cancer.A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study.Changes in biomarkers of inflammation and angiogenesis during androgen deprivation therapy for prostate cancerCastration-resistant prostate cancer: mechanisms, targets, and treatment.Emerging targeted therapies for castration-resistant prostate cancer.Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures.Targeting MET and vascular endothelial growth factor receptor signaling in castration-resistant prostate cancerPhase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial.Current treatment strategies for castration-resistant prostate cancerThe changing therapeutic landscape of castration-resistant prostate cancer.Novel therapeutics for the management of castration-resistant prostate cancer (CRPC).Emerging novel therapies for advanced prostate cancerTargeting angiogenesis for the treatment of prostate cancer.New developments in castrate-resistant prostate cancer.Bevacizumab treatment of prostate cancer.Docetaxel: a review of its use for the first-line treatment of advanced castration-resistant prostate cancer.Current and emerging treatments in the management of castration-resistant prostate cancer.Landmarks in non-hormonal pharmacological therapies for castration-resistant prostate cancer.PSA response rate as a surrogate marker for median overall survival in docetaxel-based first-line treatments for patients with metastatic castration-resistant prostate cancer: an analysis of 22 trials.Targeting Met and VEGFR Axis in Metastatic Castration-Resistant Prostate Cancer: 'Game Over'?Antibody therapeutics for treating prostate cancer: where are we now and what comes next?Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities.Phase III trials with docetaxel-based combinations for metastatic castration-resistant prostate cancer: time to learn from past experiences.Immunohistochemical expression of PDGFR, VEGF-C, and proteins of the mToR pathway before and after androgen deprivation therapy in prostate carcinoma: significant decrease after treatment.
P2860
Q26823014-6651C52B-D428-4CB2-A5E6-AF74CE471D05Q26851183-3A84ECA6-5CAD-4459-ABF8-341F41372E0DQ28534382-D26B7C0B-3876-4E0E-B97C-045F7D5C1F25Q28687241-8D0B53D9-35AA-4136-B5F1-95C83B70C375Q31060162-AE368603-7731-476E-9339-0D475EC76378Q33416977-7C51FE4B-22C8-4960-B478-344100026702Q33949406-85B955B5-7E49-4632-A6FA-A0D38777D79CQ34634763-BD701067-4375-417D-BB31-85E01A65ECC3Q35034020-180E6CD7-B6C3-4B73-9211-048FF8452F5AQ35776240-E52B1CFD-E1D9-4200-8975-24D15514BB92Q35864027-CA2A8B37-E3A0-4CA2-A726-403AFE33E5ACQ35999255-BE3638D2-83C8-4982-9F72-33EAC106DF9CQ36058291-E64DE43B-3D74-4DEE-8B40-FB959D5556D3Q36181578-7D3DD570-ADB3-4FCB-A1C1-D0D2BEE8169EQ36931715-864754F3-D5DC-45B4-9628-BD2EF04444F1Q37218730-86CBE603-00E0-48C7-A5F9-21D2A57DF501Q37860950-A8B27C31-D4F1-4EBB-A728-1CED7725826AQ37913983-B49259DF-C2CE-4C74-A926-6A6DAEF48E03Q37950459-0FB503FC-0BE5-4DA3-B8F2-5EB5D65F7739Q37980450-E05A1F6C-57DC-4E41-8AF1-DAF0EA0F7053Q37993137-CAA125D9-A9E8-4E6D-B18B-C5A0067017D4Q38016532-6AFF2C55-0F3D-49D6-A6E0-FEDCEA997AB8Q38024852-150B9D99-2980-431B-8802-A1B3B50DE054Q38028012-F1938BDD-68BE-4E70-A9F5-C51DCFE9831EQ38030595-05941FED-F972-4C50-B102-B53408DF4535Q38050465-3571FC75-280D-48D7-9FDE-AD561F60918EQ38246587-664F47CC-EBF9-4A80-A04F-9AF325392D5EQ38723404-7DE62F74-ACA2-4644-9EF6-6921CE0E7EC2Q39000185-15D8F18D-DEFE-458B-8B7E-18CA27300CD4Q39639008-F69B6A52-6493-4018-9C41-694EC113C238Q42927772-43BBF465-E50E-4B10-89FC-24C78864B623Q43867243-65376B17-14B3-48C6-ADE7-5A9E8EC1A04D
P2860
A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006.
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
A phase 2 study of estramustin ...... Leukemia Group B Study 90006.
@ast
A phase 2 study of estramustin ...... Leukemia Group B Study 90006.
@en
A phase 2 study of estramustin ...... Leukemia Group B Study 90006.
@nl
type
label
A phase 2 study of estramustin ...... Leukemia Group B Study 90006.
@ast
A phase 2 study of estramustin ...... Leukemia Group B Study 90006.
@en
A phase 2 study of estramustin ...... Leukemia Group B Study 90006.
@nl
prefLabel
A phase 2 study of estramustin ...... Leukemia Group B Study 90006.
@ast
A phase 2 study of estramustin ...... Leukemia Group B Study 90006.
@en
A phase 2 study of estramustin ...... Leukemia Group B Study 90006.
@nl
P2093
P2860
P356
P1433
P1476
A phase 2 study of estramustin ...... d Leukemia Group B Study 90006
@en
P2093
Cancer and Leukemia Group B
Ellen B Kaplan
Eric J Small
Joel Picus
Nicholas J Vogelzang
W Kevin Kelly
Walter M Stadler
P2860
P304
P356
10.1002/CNCR.25421
P407
P577
2010-09-22T00:00:00Z